Development

Articles

Although mRNA and viral vector vaccines have been top of mind for COVID-19 treatments, other technologies and treatments are emerging—along with new variants. 

What’s Next for COVID-19 Vaccines and Variants? 

Sanofi’s acquisition of Origimm Biotechnology will add to its pipeline of vaccine candidates for treating acne.

Sanofi to Acquire Origimm Biotechnology for Vaccine-based Acne Treatment

Secarna Pharmaceuticals and Achilles Therapeutics have entered into an agreement to optimize the development of T cell therapies in Achilles’ pipeline.

Secarna Pharmaceuticals and Achilles Therapeutics Partner on T Cell Therapy Development

Feliza Mirasol is the science editor for 

The biopharma industry is seeing more merit in strategizing clinical and commercial drug development as early as the preclinical phase.

Biopharma Industry is Seeing Merit in Early Preclinical Strategies

MilliporeSigma, the U.S. and Canadian Life Science business of Merck KGaA, Darmstadt, Germany, signed an agreement with Cellecta to license its genome-editing tool.




MilliporeSigma Licenses CRISPR-Cas9 Technology to Cellecta

In September, Codex DNA released a full-length synthetic genome for the SARS-CoV-2 delta variant, which may accelerate discovery and development of diagnostics and treatments for COVID-19.

Codex DNA Aims to Accelerate Virus Research with Full-Length Synthetic Genome for SARS-CoV-2 Delta Variant

GeneTx Biotherapeutics and Ultragenyx Pharmaceutical announced that FDA has removed the clinical hold on GTX-102, an investigational treatment for Angelman syndrome.

FDA Removes Clinical Hold on Phase I/II Study of Angelman Syndrome Treatment

UCR scientists are researching whether a plant-based messenger RNA vaccine can be created and aim to eliminate the need for the refrigeration of mRNA vaccines during transport and storage.

Researchers from the University of California Riverside Investigate Plant-Based mRNA Vaccines

Moderna announced a collaboration to develop a new mRNA therapeutic for Crigler-Najjar Syndrome Type 1 at no cost to patients.

Moderna and ILCM Announce Collaboration to Develop mRNA Therapeutic for CN-1

FSD Pharma has entered a definitive agreement to acquire all of the issued and outstanding shares of Lucid Psycheceuticals for approximately US$9 million (CAD$11.3 million) in FSD Pharma stock.

Early Phase Development